Phenoxybenzamine hydrochloride
-
Phenoxybenzamine hydrochloride
structure -
-
CAS No:
63-92-3
-
Formula:
C18H22ClNO.ClH
-
Chemical Name:
Phenoxybenzamine hydrochloride
-
Synonyms:
Benzenemethanamine,N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)-,hydrochloride (1:1);Benzylamine,N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)-,hydrochloride;Benzenemethanamine,N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)-,hydrochloride;2-(N-Benzyl-2-chloroethylamino)-1-phenoxypropane hydrochloride;N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine,hydrochloride;Dibenzyline hydrochloride;Phenoxybenzamine chloride;Phenoxybenzamine hydrochloride;N-2-Phenoxyisopropyl-N-benzyl-β-chloroethylamine hydrochloride;Dibenzyline chloride;Dibenzylin;Dibenzyran;NSC 37448;34238-85-2
- Categories:
-
CAS No:
Description
Phenoxybenzamine hydrochloride is a selective antagonist of both α-adrenoceptor and calmodulin that is commonly used for the treatment of hypertension, specifically caused by pheochromocytoma.
Phenoxybenzamine hydrochloride is a white crystalline powder. Melting point 137.5-140°C. Used as an antihypertensive drug.
Phenoxybenzamine hydrochloride is a white crystalline powder. Melting point 137.5-140°C. Used as an antihypertensive drug.|Phenoxybenzamine hydrochloride is an organic molecular entity.|An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.
Phenoxybenzamine hydrochloride Basic Attributes
340.29
339.115662
200-569-7
759572|37448
DTXSID0021127
2922299090
Characteristics
12.5
white powder
137.5-140 °C
381.5°C at 760 mmHg
184.5ºC
H2O: <0.01 g/100 mL at 18.5 ºC
2-8°C
194.2 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]
Light sensitive and may be sensitive to exposure to air (NTP, 1992). Insoluble in water.
Ethers
Safety Information
Ⅲ
2811
3
22-40
22-36/37/39-45
DP3750000
Xn
P301 + P312 + P330
H302-H351
Flash point data are not available for this chemical, but it is probably combustible. (NTP, 1992)
|Warning|H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]|P201, P202, P264, P270, P281, P301+P312, P308+P313, P330, P405, and P501|Aggregated GHS information provided by 40 companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.|Danger|H303: May be harmful if swallowed [Warning Acute toxicity, oral]|P201, P202, P260, P261, P264, P270, P272, P280, P281, P302+P352, P307+P311, P308+P313, P312, P321, P333+P313, P363, P405, and P501
Fires involving this compound should be controlled using a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992)
SMALL SPILLS AND LEAKAGE: Should a spill occur while you are handling this chemical, FIRST REMOVE ALL SOURCES OF IGNITION, then you should dampen the solid spill material with 60-70% ethanol and transfer the dampened material to a suitable container. Use absorbent paper dampened with 60-70% ethanol to pick up any remaining material. Seal the absorbent paper, and any of your clothes, which may be contaminated, in a vapor-tight plastic bag for eventual disposal. Solvent wash all contaminated surfaces with 60-70% ethanol followed by washing with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned. STORAGE PRECAUTIONS: You should protect this chemical from exposure to light. Keep the container tightly closed under an inert atmosphere, and store under refrigerated temperatures. (NTP, 1992)
RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with a combination filter cartridge, i.e. organic vapor/acid gas/HEPA (specific for organic vapors, HCl, acid gas, SO2 and a high efficiency particulate filter). (NTP, 1992)
Drug Information
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)|Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)|Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
SYMPTOMS: Symptoms of exposure to this compound include nasal congestion, miosis, postural hypotension, tachycardia, gastrointestinal irritation, drowsiness and fatigue. ACUTE/CHRONIC HAZARDS: When heated to decomposition this compound emits very toxic fumes of NOx and chloride ion. It is a positive animal carcinogen. (NTP, 1992)
EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop. SKIN: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment. INHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. IMMEDIATELY call a physician and be prepared to transport the victim to a hospital even if no symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Apparatus (SCBA) should be used; if not available, use a level of protection greater than or equal to that advised under Protective Clothing. INGESTION: DO NOT INDUCE VOMITING. If the victim is conscious and not convulsing, give 1 or 2 glasses of water to dilute the chemical and IMMEDIATELY call a hospital or poison control center. Be prepared to transport the victim to a hospital if advised by a physician. If the victim is convulsing or unconscious, do not give anything by mouth, ensure that the victim's airway is open and lay the victim on his/her side with the head lower than the body. DO NOT INDUCE VOMITING. IMMEDIATELY transport the victim to a hospital. OTHER: Since this chemical is a known or suspected carcinogen you should contact a physician for advice regarding the possible long term health effects and potential recommendation for medical monitoring. Recommendations from the physician will depend upon the specific compound, its chemical, physical and toxicity properties, the exposure level, length of exposure, and the route of exposure. (NTP, 1992)
Dibenylene
Phenoxybenzamine hydrochloride Use and Manufacturing
N-(phenoxyisopropyl)-N-benzyl ethanolamine was dissolved in dichloromethane (810 ml) at 25-30°C and slowly added thionyl chloride (70.0 g; 0.588 moles) at 0- 5°C. The reaction mass was stirred at 25-30°C for 2 hours and concentrated under reduced pressure at 30-35°C and residue was dissolved in acetone (570 ml) at 25- 30°C for solid formation. Filtered the solid and washed with chilled acetone (190 ml) and was dried at 45-50°C under vacuum to get 125.4 g of pure Phenoxybenzamine hydrochloride as a white solid (HPLC purity >99 percent).
An irreversible α-antagonist.Used in the treatment of hypertension, it has a relatively slow onset and prolonged effect when compared to alternative α-blockers.
Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients
Computed Properties
Molecular Weight:340.3
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:2
Rotatable Bond Count:8
Exact Mass:339.1156697
Monoisotopic Mass:339.1156697
Topological Polar Surface Area:12.5
Heavy Atom Count:22
Complexity:262
Undefined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:2
Compound Is Canonicalized:Yes
Drug Function and Efficacy
Phenoxybenzamine hydrochloride tablets are long-acting α-receptor blockers (α1, α2). They act on postganglionic α-adrenaline receptors to prevent or reverse the effects of endogenous or exogenous catecholamines, causing peripheral vasodilation and increased blood flow. Blood pressure drops slightly when lying down and can drop significantly when standing upright. A drop in blood pressure can reflexively cause an increase in heart rate.
Registered Holders
-
SS PHARMA LLC
Active
United States
-
NAVINTA LLC
Active
United States
-
MATRIX PHARMACORP PRIVATE LTD
Active
United States
Recommended Suppliers of Phenoxybenzamine hydrochloride
-
CN
5 YRS
Business licensedTrader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives
Learn More Other Chemicals
-
4H-1-Benzopyran-4-one, 2-[4-[3-(dibutylamino)propoxy]-3,5-dimethylbenzoyl]-, hydrochloride (1:1)
67652-33-9
-
Cyclopropanecarboxylic acid, 1-amino-2-ethenyl-, ethyl ester, hydrochloride (9CI)
681807-60-3
-
CYCLOPENTYL-(3,4,5-TRIMETHOXY-BENZYL)-AMINE HYDROCHLORIDE
1052525-88-8
-
2-Cyclopropylbenzenemethanamine hydrochloride Formula
118184-64-8
-
Des[4-(2-cycloproylMethoxy)] Betaxolol Hydrochloride Formula
464877-45-0
-
Ethanamine, 2-(decylthio)-, hydrochloride (1:1) Formula
36362-09-1
-
4,7-Dichloro-2-propylquinoline hydrochloride Structure
1204812-22-5
-
6,7-Dichloro-4-hydrazino-2-methylquinoline hydrochloride Structure
1170377-12-4
-
What is 2,8-Diazaspiro[4.5]decan-1-one, 2-[(4-bromophenyl)methyl]-, hydrochloride (1:1)
832710-56-2
-
What is 6,7-Dichloro-4-hydrazinoquinoline hydrochloride
1171843-02-9